Abstract PS1-13-29: Carcinoembryonic antigen (CEA), Cancer Antigen 15.3 (CA 15.3), and 18-FDG-PET in Early Breast Cancer Follow-up: Findings from the KRONOS Trial
C. Zamagni, R. Wirtz, Torri, D. Sartori et autres
1 citationClinical Cancer Research
S. Quercia
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
19Publications signalées
142Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Medical Imaging Techniques and ApplicationsBreast Cancer Treatment StudiesRadiomics and Machine Learning in Medical ImagingOvarian cancer diagnosis and treatmentAdvanced Breast Cancer Therapies
Publications récentes
ESR1 analysis of liquid biopsy in breast cancer, one-year routine experience of an Italian clinical referral center
Thais Maloberti, Laura Poppi, Giulia Ciccimara, Sara Coluccelli et autres
2 citationsThe Journal of Liquid Biopsy
Randomized Phase II/III Trial Of 3 Vs 6 Courses Of Neoadjuvant Carboplatin-Paclitaxel Chemotherapy In Stage IIIC Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma
C. Zamagni, Anna Fagotti, Daniela Rubino, Vanda Salutari et autres
2 citationsInternational Journal of Gynecological Cancer
Three-monthly dynamic evaluation of CEA and CA15-3 and 18-FDG PET vs usual practice in the follow-up of early breast cancer patients: a prospective, multicenter, randomized trial (KRONOS – Patient-Oriented New Surveillance-Study Italy)
Elena Barbieri, María Gión, Luigi Mariani, P Stieber et autres
1 citationAnnals of Oncology
CEA, CA15.3 and 18-FDG PET in the follow-up of early breast cancer (BC) patients (pts): A prospective, multicentric, randomized trial—KRONOS patient-oriented new surveillance study Italy.
Claudio Zamagni, M. Gion, Luigi Mariani, P Stieber et autres
5 citationsJournal of Clinical Oncology
Abstract OT3-05-01: Three-monthly dynamic evaluation of CEA and CA15-3 (followed by 18-FDG PET) vs usual practice in the follow-up of early breast cancer (BC) patients (pts): A prospective randomized trial (KRONOS-patient-oriented new surveillance study, Italy)
C. Zamagni, María Gión, Luigi Mariani, P Stieber et autres
0 citationsCancer Research
Reply to “18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography in predicting pathologic complete response after neoadjuvant chemotherapy: The early metabolic response is the answer”
G Zucchini, S. Quercia, Claudio Zamagni, Donatella Santini et autres
0 citationsEuropean Journal of Cancer
Potential utility of early metabolic response by 18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography in a selected group of breast cancer patients receiving preoperative chemotherapy
G Zucchini, S. Quercia, Claudio Zamagni, Donatella Santini et autres
41 citationsEuropean Journal of Cancer
Might Early Metabolic Response by 18F-FDG-PET/CT be Useful to Select Patients (PTS) With Breast Cancer (BC) who Will not Optimally Respond to Preoperative Chemotherapy (PCT)?
G Zucchini, S. Quercia, Claudio Zamagni, Donatella Santini et autres
0 citationsAnnals of Oncology
Explorative Study on the Predictive and Prognostic Value of Early Complete Metabolic Response By FDG-PET–CT During Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer
Andrea Martoni, Marta Rosati, Claudio Zamagni, Pierandrea De Iaco et autres
3 citationsClinical Ovarian and Other Gynecologic Cancer
Predictive role of [18F]FDG-PET early evaluation in patients (pts) undergoing preoperative chemotherapy (PCT) for breast cancer (BC).
Andrea Martoni, C. Zamagni, S. Quercia, Marta Rosati et autres
1 citationJournal of Clinical Oncology
Early 18F‐2‐fluoro‐2‐deoxy‐d‐glucose positron emission tomography may identify a subset of patients with estrogen receptor‐positive breast cancer who will not respond optimally to preoperative chemotherapy
Andrea Martoni, Claudio Zamagni, S. Quercia, Marta Rosati et autres
61 citationsCancer
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.